Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intermediate Dose Cytarabine Plus Idarubicin in Relapsed AML
NCT00003758Phase 2Unknown
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Dec 1998
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of cytarabine, idarubicin in acute myeloid leukemia (AML), sponsored by European Organisation for Research and Treatment of Cancer. Status: unknown.
02
Drugs
cytarabineidarubicin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00003758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003758.